Tardive Dyskinesia Training Program for Pharmacists
This training program is for pharmacists only. If you are a Pharmacy Technician, please enroll in the appropriate training program here: https://elearning.ashp.org/products/14120/
ACPE Number:0204-0000-26-408-H01-P Content Release Date: June 30, 2026 Expiration Date: June 30, 2029 Activity Type: Application-based CE Credits: 6.0 contact hours (0.6 CEUs) Activity Fee: Free
Activity Overview
In the United States, antipsychotics are the foundation for schizophrenia treatment and are gaining additional indications expanding to a broader patient population. Tardive dyskinesia (TD) is a potentially irreversible, severe adverse effect of dopamine-receptor blocking agents including antipsychotics that can lead to functional impairment and decreased quality of life. Routine monitoring and assessment for TD is recommended for early identification and intervention, but as many as 60-95% of patients with TD are undiagnosed, leading to missed treatment opportunities and adverse clinical outcomes.
Pharmacists are front-line clinicians who often have more interaction with patients than their primary care providers. This TD training program will discuss signs, symptoms, and burdens of TD and provide an overview of TD risk factors including dopamine receptor blocking agents with a focus on antipsychotics and their associated risk. The training will incorporate Abnormal Involuntary Movement Scale (AIMS) assessment examples allowing pharmacists to recognize and score symptoms of TD. The program will also discuss next steps once TD is identified such as collaboration with the healthcare team and the role of vesicular monoamine transporter 2 (VMAT2) inhibitors. This education is designed to build confidence for pharmacists in identifying patients with TD and collaborating with their healthcare teams to improve patient outcomes.
The American Society of Health-System Pharmacists is accredited by the Accreditation Council for Pharmacy Education as a provider of continuing pharmacy education with Commendation.
This training program was planned to meet the educational needs of pharmacists who work in hospitals, health systems, ambulatory clinics, and specialty pharmacies who care for or are interested in the care of patients with or who may be at risk for tardive dyskinesia.
At the conclusion of this activity, participants should be able to:
Module 1: Introduction to Tardive Dyskinesia
Summarize the signs, symptoms, and onset of tardive dyskinesia
Identify the burden of disease for tardive dyskinesia and barriers to identifying patients with tardive dyskinesia
Compare different dopamine-receptor blocking agents and their risk for tardive dyskinesia
Assess antipsychotic use across different indications to identify patients at risk for tardive dyskinesia
Module 2: Identifying Patients with Tardive Dyskinesia
Identify patient-specific risk factors to determine which individuals may be at increased risk for developing tardive dyskinesia
Describe the role of a pharmacist and pharmacy technician in identifying tardive dyskinesia and incorporating movement disorder screening into practice
Differentiate tardive dyskinesia from other movement disorders by applying patient history, symptoms, and case examples.
Apply effective counseling strategies to educate patients taking dopamine-receptor blocking agents about the risks, signs, and symptoms of tardive dyskinesia.
Recommend patients to be assessed for tardive dyskinesia based on observable signs, patient history, and medication use.
Module 3: The AIMS Assessment
Prioritize screening patients who are at risk of developing tardive dyskinesia
Implement the AIMS Assessment to screen patients who are at risk of developing tardive dyskinesia and develop a long-term monitoring plan involving the use of structured AIMS assessments
Compare the signs and symptoms of patients experiencing different intensity levels of tardive dyskinesia
Module 4: The Management of Tardive Dyskinesia
Recommend appropriate next steps for patients with suspected or confirmed tardive dyskinesia by collaborating with the interprofessional clinical team.
Evaluate the role of VMAT2 inhibitors in tardive dyskinesia treatment based on symptom severity.
Apply clinical evidence and guideline recommendations to appropriately manage patients with tardive dyskinesia.
StevenClark Stoner, PharmD, BCPP, FAAPP Activity Chair Associate Dean for Student Affairs and Clinical Professor UMKC School of Pharmacy Kansas City, Missouri
Steven Stoner is a Clinical Professor and the Associate Dean for Student Affairs at the University of Missouri-Kansas City (UMKC) School of Pharmacy in Kansas City, Missouri. He earned his Doctor of Pharmacy degree from the University of Nebraska College of Pharmacy in 1994 and completed a Psychiatric Pharmacy Residency and Fellowship at Western Missouri Mental Health Center. Dr. Stoner served as the Director of a Psychiatric Pharmacy Practice residency program for 10 years (1998-2008) at the Northwest Missouri Psychiatric Rehabilitation Center in St. Joseph, Missouri. Dr. Stoner has been a member of the American Association of Psychiatric Pharmacists (AAPP) since 1997 and has served on numerous committees, including terms on the Board of Directors as Member-at-Large and President (2010-2011). He was recently named a Fellow of AAPP.
Austin Campbell, PharmD, BCPP, FAAPP Clinical Associate Professor UMKC School of Pharmacy at MU Columbia, Missouri
Austin Campbell is a Clinical Associate Professor at the University of Missouri-Kansas City and an Adjunct Assistant Professor at the University of Missouri School of Medicine in Columbia, Missouri. With over 15 years of experience in inpatient and ambulatory psychiatric care, he is a widely published author and frequent national speaker. Dr. Campbell serves on the American Association of Psychiatric Pharmacists (AAPP) Board of Directors and was honored as the 2025 Missouri Society of Health-System Pharmacists (MSHP) Pharmacist of the Year.
In accordance with our accreditor’s Standards of Integrity and Independence in Accredited Continuing Education, ASHP requires that all individuals in control of content disclose all financial relationships with ineligible companies. An individual has a relevant financial relationship if they have had a financial relationship with an ineligible company in any dollar amount in the past 24 months and the educational content that the individual controls is related to the business lines or products of the ineligible company.
An ineligible company is any entity producing, marketing, re-selling, or distributing health care goods or services consumed by, or used on, patients. The presence or absence of relevant financial relationships will be disclosed to the activity audience.
The following person in control of this activity’s content has relevant financial relationships:
Steven Stoner: Speaker’s Bureau – Neurocrine Biosciences; Advisor – Alkermes Pharmaceuticals, Neurocrine Biosciences; Principal Investigator – Otsuka Pharmaceuticals
All other persons in control of content do not have any relevant financial relationships with an ineligible company. As defined by the Standards of Integrity and Independence in Accredited Continuing Education definition of ineligible company. All relevant financial relationships have been mitigated prior to the CE activity.
To receive CE credit, complete the steps below within 60 days of completing the activity.
View all modules and answer all polling questions with a passing score of at least 70% on the assessment for each module.
Complete the evaluation.
Verify credits were successfully transferred to CPE Monitor before the ACPE 60-day deadline by checking your NABP eProfile account.
Important Note – ACPE 60 Day Deadline Per ACPE requirements, CPE credit must be claimed within 60 days of being earned – no exceptions! To verify that you have completed the required steps and to ensure your credits have been reported to CPE Monitor, we encourage you to check your NABP eProfile account to validate your credits were transferred successfully before the ACPE 60-day deadline. After the 60 day deadline, ASHP will no longer be able to award credit for this activity.
Provided by ASHP.
Supported by an independent educational grant from Teva Pharmaceuticals.
